Medication info

Inizentaduo Tablet 2.5/850 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Vivozon Pharmaceutical Co., Ltd.
Appearance
Bright orange, biconvex, oval film-coated tablet
Packaging
60 tablets/box [10 tablets/PTP×6]
Approval status
Expired

MFDS item code 202001550 · Approved 2020.03.05

This product's status changed to Expired on 2025.03.05. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of the individual components: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medication 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medication 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should take the same doses of linagliptin and metformin that they were previously taking as the initial dose. 3. Patients who do not achieve adequate glycemic control with combination therapy with insulin and metformin: The initial dose of this medication should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administer with caution to the following patients). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral hypoglycemic agents to this medication. Any change in treatment for type 2 diabetes may cause a change in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, provided the dose is adjusted as follows. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Do not administer to the following patients).

Ingredients

Manufacturer
Vivozon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Difficulty in blood sugar control in patients with type 2 diabetes
View approved original text

This medication is used to assist in blood sugar control for adults with type 2 diabetes. It is especially administered when prior treatment with diabetes medication has not been undertaken, or when it is difficult to control blood sugar with monotherapy. It can also be used when adequate effect cannot be achieved with monotherapy using metformin, or when replacing the combination of linagliptin and metformin. Moreover, it is used when blood sugar control is difficult even with maximum doses of metformin alongside sulfonylureas or insulin, in order to enhance therapeutic efficacy. If there is a need for combination therapy with empagliflozin, this medication is also administered. This medication improves blood sugar control in individuals with type 2 diabetes in conjunction with diet and exercise.

How to take

Adult dose

The dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of the individual components: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medication 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medication 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should take the same doses of linagliptin and metformin that they were previously taking as the initial dose. 3. Patients who do not achieve adequate glycemic control with combination therapy with insulin and metformin: The initial dose of this medication should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administer with caution to the following patients). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral hypoglycemic agents to this medication. Any change in treatment for type 2 diabetes may cause a change in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, provided the dose is adjusted as follows. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Do not administer to the following patients).

Precautions

This medication can cause a rare side effect known as lactic acidosis, which is serious and can lead to death if treatment is delayed. It should not be used in certain patients, for example, those with allergies to its components, type 1 diabetes, lactic acidosis, diabetic ketoacidosis, or severe renal impairment. Patients with compromised renal function, acute infections, dehydration, severe trauma, shock, or acute myocardial infarction—conditions that may affect renal function—should use this medication with caution. It is not recommended for use in pregnant women or those who may become pregnant, as well as nursing mothers. When used with other blood glucose-lowering medications, there is an increased risk of hypoglycemia, so careful monitoring of blood sugar levels is necessary. To reduce the risk of lactic acidosis, renal function should be regularly checked and this medication temporarily stopped in situations that could cause dehydration or acute renal damage. If symptoms such as muscle cramps, abdominal pain, or severe fatigue occur during the use of this medication, it is important to inform a doctor immediately. This medication may reduce vitamin B12 levels, so it is necessary to periodically check vitamin B12 concentrations in the blood during long-term use. In addition, this medication may interact with some drugs, so it is essential to consult a doctor or pharmacist if taking other medications. If iodine-containing contrast agents are used for surgery or radiologic examinations, this medication should be discontinued for a certain period before and after the examination and resumed only after renal function is restored. Elderly patients are prone to renal function decline, so renal function should be frequently checked, and dosage adjustments may be needed when taking this medication. During the treatment, if blistering skin diseases or severe joint pain occurs, consult a physician immediately. Finally, this medication is not recommended for use in children or children under 10 years of age.

Side effects

Lactic acidosis, nasopharyngitis, hypersensitivity, angioedema, urticaria, decreased and deficient vitamin B12, hypoglycemia, taste disturbance, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer formation, abnormal liver function tests, hepatitis, pruritus, erythema, rash, vesicular pemphigoid, joint pain accompanied by severe symptoms and disability, rhabdomyolysis, increased lipase, increased amylase, constipation, epigastric pain, small bowel colitis, bowel obstruction, gastroenteritis, shingles, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, speech disturbance, Alzheimer's dementia, chest pain, fever, facial swelling, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscal injury, pneumoconiosis, congestive heart failure, angina pectoris, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, anxiety, affective disorder, insomnia, depression, contusion, bone contusion, concussion, bone fracture, hand fracture, pruritus, hypertension, benign prostatic hyperplasia, angina pectoris, acute myocardial infarction, unstable angina, stomatitis, mediastinitis, vitreous hemorrhage, fever, ligament sprain, flank pain, myelodysplastic syndrome, vocal cord polyp, dyspepsia, rectal bleeding, cheilitis, dental caries, enteritis, gastritis, dizziness, somnolence, discomfort in the chest, weakness, pain, nosebleed, oropharyngeal pain, voice disturbance, nasal bleeding, hearing loss, erectile dysfunction, thyroid enlargement, confusional state, nocturia, dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly closed container. The storage temperature should be maintained between 1 and 30 degrees Celsius at room temperature. Storing it this way will help maintain its effectiveness for a long time.

Appearance and packaging

Appearance

Bright orange, biconvex, oval film-coated tablet

Package unit

60 tablets/box [10 tablets/PTP×6]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.